Alexandra Bazeos
Overview
Explore the profile of Alexandra Bazeos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim E, Jiang Y, Xu T, Bazeos A, Knapp A, Bolen C, et al.
BMC Cancer
. 2022 Mar;
22(1):231.
PMID: 35236331
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defined using a number of well-established molecular subsets. Application of non-negative matrix factorization (NMF) to whole exome sequence data has...
2.
Samineni D, Huang W, Gibiansky L, Ding H, Zhang R, Li C, et al.
Adv Ther
. 2021 Nov;
39(1):598-618.
PMID: 34822104
Introduction: Outcomes remain poor in patients with diffuse large B cell lymphoma (DLBCL) who overexpress BCL-2 protein. We present population pharmacokinetics (PopPK) and exposure-response (ER) analyses for venetoclax (a selective...
3.
Morschhauser F, Feugier P, Flinn I, Gasiorowski R, Greil R, Illes A, et al.
Blood
. 2021 Feb;
137(5):600-609.
PMID: 33538797
The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L)...
4.
Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink A, et al.
Am J Hematol
. 2019 Jun;
94(9):1002-1006.
PMID: 31222797
In CLL, progressive disease (PD) following remission after first line treatment can present with varying phenotypes. We hypothesized that the mode of PD correlates with clinical outcomes. Data from three...
5.
Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, et al.
Haematologica
. 2019 May;
104(12):2400-2409.
PMID: 31073075
There are no validated molecular biomarkers to identify newly-diagnosed individuals with chronic-phase chronic myeloid leukemia likely to respond poorly to imatinib and who might benefit from first-line treatment with a...
6.
Klanova M, Oestergaard M, Trneny M, Hiddemann W, Marcus R, Sehn L, et al.
Clin Cancer Res
. 2019 May;
25(15):4634-4643.
PMID: 31053601
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood...
7.
Mughal T, Vannucchi A, Soverini S, Bazeos A, Tibes R, Saglio G, et al.
Haematologica
. 2014 May;
99(5):797-801.
PMID: 24790057
No abstract available.
8.
de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al.
Blood
. 2013 May;
122(2):227-38.
PMID: 23719297
Tyrosine kinase inhibitors (TKIs) have significant off-target multikinase inhibitory effects. We aimed to study the impact of TKIs on the in vivo B-cell response to vaccination. Cellular and humoral responses...
9.
Lowe R, Gemma C, Beyan H, Hawa M, Bazeos A, Leslie R, et al.
Epigenetics
. 2013 Mar;
8(4):445-54.
PMID: 23538714
There is increasing evidence that interindividual epigenetic variation is an etiological factor in common human diseases. Such epigenetic variation could be genetic or non-genetic in origin, and epigenome-wide association studies...
10.
Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M, et al.
J Clin Oncol
. 2010 Apr;
28(14):2381-8.
PMID: 20385986
Purpose: There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy...